Drug facts
MoleculePotassium Chloride
Generics already compete: 34 makers on the market. 118 A-rated products from 34 makers substitute at the counter.
K-Tab was first approved by the FDA before 1982 under NDA 018279; the application holder is Abbvie Inc. The Orange Book lists NDA 018279 as discontinued.
The latest NADAC for POTASSIUM CHLORIDE 10% (20 MEQ/15 ML) ORAL LIQUID is $0.04 per mL (as of 10/28/2026).
Holder Abbvie IncApplication NDA 018279Approved before 1982
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No K-Tab patent listed in the Orange Book Orange Book
- Later patents, other products
- Potassium Chloride (NDA 206814) 03/07/2039 Orange Book
02Competition
- Generics
- 34 generic makers Orange Book
- First generic approved
- before 1982 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Potassium Chloride profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.04 per mLPOTASSIUM CHLORIDE 10% (20 MEQ/15 ML) ORAL LIQUID, as of 10/28/2026 CMS NADAC
- Latest recall
- 10/29/2025Class I, Potassium Chloride, Otsuka Icu Medical LLC FDA enforcement
04Product
- Application holder
- Abbvie Inc Orange Book
- Application
- NDA 018279 Orange Book
- First approved
- before 1982 Orange Book
- Dosage forms
- capsule, extended release; for solution; injectable; solution; tablet, extended release
- Routes
- injection, oral
- Other brand names
- Klor-ConKlor-Con M10Klor-Con M15Klor-Con M20Pokonza
- Status
- NDA 018279 discontinued Orange Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.